KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602).

Jonathan R Strosberg, Tyler Zemla, Susan Geyer, Sydney Pulsipher, Fang-Shu Ou, Spencer Behr, Nitya Raj, Namrata Vijayvergia, Arvind Dasari, Eileen M O'Reilly, Jeffrey A Meyerhardt, Edward M Wolin, Thorvardur R Halfdanarson, Jennifer A Chan

Endocr Relat Cancer 33(1) e250415

PMID41524552
PMCIDPMC12872296
DOI10.1530/ERC-25-0415
发表日期2026-01-12
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

Well-differentiated grade 3 neuroendocrine tumors (NETs) have recently been described as a distinct category, and randomized data regarding efficacy of therapy for these patients are scarce. In the phase 3 CABINET trial, cabozantinib improved PFS compared with placebo in patients with advanced, previously treated, progressive extra-pancreatic NETs (epNETs) and pancreatic NETs (pNETs) of all grades. Here, we evaluate if these results remain consistent in a subgroup of patients with well-differentiated G3 NETs. Patients with locally advanced or metastatic epNETs or pNETs were randomized 2:1 in independent cohorts to receive cabozantinib 60 mg daily vs placebo. We analyzed outcomes of the subset of patients with G3 NETs (Ki-67 > 20%), combining patients in the pNET and epNET cohorts due to small sample sizes. Twenty-four patients had G3 NETs, 16 randomized to cabozantinib and 8 to placebo. Primary sites included pancreas (n = 12), GI tract (n = 7), unknown primary sites (n = 3), and lung/thymus (n = 2). Median PFS for patients with G3 NETs treated with cabozantinib was 7.9 vs 3 months with placebo (HR = 0.15, 95% CI: 0.04-0.57, 1-sided log-rank P = 0.0034). The confirmed overall radiographic response rate was 25% (4/16) with cabozantinib vs 0% (0/8) with placebo. Safety outcomes were consistent with published data for the trial as a whole. Subset analysis of the CABINET trial showed improved PFS associated with cabozantinib vs placebo for G3 NETs of pancreatic and extra-pancreatic origin. Despite limited numbers, these results suggest that cabozantinib can be an effective option for patients with advanced G3 NETs. ClinicalTrials.gov Identifier: NCT03375320.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1

Figure 1: Progression-free survival: cabozantinib versus placebo

Figure_1_Progression-free_survival_cabozantinib_versus_placebo

Progression-free survival

Figure 1 · Panel Figure_1_Progression-free_survival_cabozantinib_versus_placebo

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Figure_1_Progression-free_survival_cabozantinib_versus_placebo 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:extreme upward reversal曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Figure 2: Waterfall plot illustrating best radiographic response of 19 evaluable patients: pNET patients (red) on cabozantinib (solid box) or placebo (checkered box). epNET patients (blue) on cabozantinib (solid box) or placebo (checkered box).
非 KM Figure